Enrofloxacin Hydrochlorid
Product Description
Enrofloxacin Hydrochlorid, Enrofloxacin HCL
CAS number： 93106-60-6
Molecular formula： C19H22FN3O3
Molecular weight： 359.39
Packing: 25kg/drum
Shelf Life: 3 years
Specification:
Tests | Acceptance Criteria | Results | |
Description | Slightly yellow or pale orange yellow crystalline powder, odorless,slightly bitter;becoming orange-red on exposure to light. | Slightly yellow crystalline powder | |
Freely soluble in chloroform and in sodium hydroxide TS , slightly soluble in methanol , very slightly soluble in water , sparingly soluble in dimethylformamide. |
/ | ||
Melting range | 221～226℃ | 223.0-223.5℃ | |
Identification | HPLC：Similar in retention time to the principal peak of the reference. |
Conforms | |
IR：Conforms to the reference spectrum. | |||
Clarity of solution | Clear （1g/20ml in 0.5mol/Lin NaOH Solution） | Conforms | |
Color of solution | Not more intensely coloured than GY4 or Y4 （1g/20ml in 0.5mol/Lin NaOH Solution） | Conforms | |
Fluoroquinolonic acid （TLC） | ≤0.2% | Conforms | |
Related substance（HPLC） | （1） Ciprofloxacin | ≤0.5% | 0.02% |
（2） Any other single impurity | ≤0.3% | 0.13% | |
（3） Total impurities | ≤0.7% | 0.13% | |
Loss on drying | ≤0.5%(105℃) | 0.09% | |
Residue on ignition | ≤0.2% | ＜0.01% | |
Heavy metals | ≤20ppm | ＜20ppm | |
Assay | C19H22FN3O3 99.0~101.0% （Dried substance） | 99.9% | |
Conclusion: conforms to Chinese Veterinary Pharmacopoeia 2015 (Ⅰ) specification for enrofloxacin base. | |||
Description:Enrofloxacin is a broad spectrum bactericidal drugs, have special effects on mycoplasma. White on escherichia coli, klebsiella bacillus coli, pseudomonas aeruginosa, salmonella, deformation, haemophilus, kill, pasteurella, streptococcus hemolytic pap coli, s. aureus bacteria, such as have antiseptic effect.
Function:
Dogs and Cats
The product is indicated in the treatment of bacterial infections of the alimentary, respiratory and urogenital tracts, skin, secondary wound infections and otitis externa where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.
Cattle
Diseases of the respiratory and alimentary tract of bacterial or mycoplasmal origin (e.g. pasteurellosis, mycoplasmosis, coli-bacillosis, coli-septicaemia and salmonellosis) and secondary bacterial infections subsequent to viral conditions (e.g. viral pneumonia) where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.
Pigs
Diseases of the respiratory and alimentary tract of bacterial or mycoplasmal origin (e.g. pasteurellosis, actinobacillosis, mycoplasmosis, coli-bacillosis, coli-septicaemia and salmonellosis) and mulifactorial diseases such as atrophic rhinitis and enzootic pneumonia, where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.